Novosibirsk State Medical University is a medical university in Novosibirsk, Russia for training qualified doctors. It was organized in 1935 when the medical faculty was opened. Until 1999 it was known as the Novosibirsk medical institute. From 1999 to 2005 it is the Novosibirsk state medical academy.

During the past decade, State Novosibirsk Regional Clinical Hospital conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 15 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 12 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "State Novosibirsk Regional Clinical Hospital" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Abbott Nutrition" with 3 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Celgene" with 3 trials sponsored and "Gilead Sciences" with 3 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "State Novosibirsk Regional Clinical Hospital" #1 collaborator was "OCT Clinical Trials" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator, "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator and "Kuban State Medical University" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "State Novosibirsk Regional Clinical Hospital" are "Acromegaly" (6 trials), "Multiple Sclerosis" (3 trials), "Type 2 Diabetes Mellitus" (3 trials), "Asthma" (2 trials) and "Chronic Obstructive Pulmonary Disease" (2 trials). Many other conditions were trialed in "State Novosibirsk Regional Clinical Hospital" in a lesser frequency.

Most popular intervention types in "State Novosibirsk Regional Clinical Hospital" are "Drug" (35 trials), "Other" (8 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "BMS-986165" (2 trials), "CAM2029 (octreotide subcutaneous depot)" (2 trials), "Fenebrutinib" (2 trials) and "Lebrikizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "State Novosibirsk Regional Clinical Hospital" are 40 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "State Novosibirsk Regional Clinical Hospital". undefined are not yet recruiting, 6 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in State Novosibirsk Regional Clinical Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in State Novosibirsk Regional Clinical Hospital, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".